Melanoma Canada is gathering information from patients diagnosed with Cutaneous Squamous cell carcinoma (cSCC) to help us prepare a group submission to Canada's Drug Agency (CDA) on the experiences and opinions of patients and their caregivers for a new adjuvant treatment therapy being proposed for patients. Adjuvant therapy is cancer treatment that's given after primary treatments, such as surgery when there is no further evidence of disease. The drug under review is cemiplimab (Libtayo) which is an anti-pd1 immunotherapy indicated for the treatment of patients with CSCC.
The Canada's Drug Agency (CDA) is the national organization responsible for providing independent, evidence-based, and actionable information about drugs and health technologies in Canada. An expert advisory body of the CDA known as the pan-Canadian Oncology Drug Review Expert Review Committee (pERC), reviews all cancer drugs and makes evidence-based funding recommendations for the provinces to guide funding decisions (except Quebec). The process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient and clinician perspectives.
This survey should take about 10-12 minutes to complete. The results of this survey will assist Melanoma Canada to prepare a patient group submission. For more information, please contact Melanoma Canada directly at 1-800-560-8035, or support@melanomacanada.ca
All information collected by Melanoma Canada, will be compiled and consolidated into a report prior to submission. In order to ensure patient privacy, individual responses, and names or contact information will not be identifiable. Patient information will not be shared with any other external organisations or for any purpose other than this submission. Selected quotes may be used without reference to names or other identifying information.
We thank you in advance for your help in providing this information and for helping to advance the interests of patients across this country. This information is critical to help broaden patient access to treatments and is very important for the approval for funding of these drug therapies.
Sincerely,
Melanoma Canada
